These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 2836619)

  • 1. A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus.
    Miller N; Hutt-Fletcher LM
    J Virol; 1988 Jul; 62(7):2366-72. PubMed ID: 2836619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells.
    Haddad RS; Hutt-Fletcher LM
    J Virol; 1989 Dec; 63(12):4998-5005. PubMed ID: 2555536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus lacking glycoprotein gp85 cannot infect B cells and epithelial cells.
    Oda T; Imai S; Chiba S; Takada K
    Virology; 2000 Oct; 276(1):52-8. PubMed ID: 11021994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of antibodies to the Epstein-Barr virus glycoprotein gp85 with a synthetic peptide corresponding to a sequence in the BXLF2 open reading frame.
    Oba DE; Hutt-Fletcher LM
    J Virol; 1988 Apr; 62(4):1108-14. PubMed ID: 2831373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
    Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
    Front Immunol; 2018; 9():932. PubMed ID: 29765376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
    Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
    Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
    J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization of lymphocyte immortalization by different strains of Epstein-Barr virus with a murine monoclonal antibody.
    Miller G; Heston L; Hoffman G
    Infect Immun; 1982 Sep; 37(3):1028-31. PubMed ID: 6182100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein.
    Yaswen LR; Stephens EB; Davenport LC; Hutt-Fletcher LM
    Virology; 1993 Aug; 195(2):387-96. PubMed ID: 8393232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.
    Thorley-Lawson DA; Geilinger K
    Proc Natl Acad Sci U S A; 1980 Sep; 77(9):5307-11. PubMed ID: 6254073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.
    Tanner J; Whang Y; Sample J; Sears A; Kieff E
    J Virol; 1988 Dec; 62(12):4452-64. PubMed ID: 2460635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
    Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
    J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
    Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
    Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.
    Hoffman GJ; Lazarowitz SG; Hayward SD
    Proc Natl Acad Sci U S A; 1980 May; 77(5):2979-83. PubMed ID: 6248876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus.
    Snijder J; Ortego MS; Weidle C; Stuart AB; Gray MD; McElrath MJ; Pancera M; Veesler D; McGuire AT
    Immunity; 2018 Apr; 48(4):799-811.e9. PubMed ID: 29669253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.
    Khyatti M; Patel PC; Stefanescu I; Menezes J
    J Virol; 1991 Feb; 65(2):996-1001. PubMed ID: 1846213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein.
    Qualtiere LF; Chase R; Vroman B; Pearson GR
    Proc Natl Acad Sci U S A; 1982 Jan; 79(2):616-20. PubMed ID: 6176998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.
    Sairenji T; Bertoni G; Medveczky MM; Medveczky PG; Nguyen QV; Humphreys RE
    J Virol; 1988 Aug; 62(8):2614-21. PubMed ID: 2839689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
    Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
    Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.
    Thorley-Lawson DA; Poodry CA
    J Virol; 1982 Aug; 43(2):730-6. PubMed ID: 6287039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.